Ticagrelor Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ticagrelor Market Trends and Insights

Persistent Cardiovascular Event Burden Sustains Baseline Demand

Ischemic heart disease remained the leading cause of cardiovascular mortality in 2023. This disease burden gives the ticagrelor market a stable clinical base because acute coronary events require prompt antiplatelet treatment. Better access to reperfusion care can increase the population that survives an event and needs secondary prevention afterward. Global cardiovascular deaths are projected to rise from 20.5 million in 2025, even as age-standardized mortality rates decline, which points to continued growth in absolute treatment need.^{[2]European PMC, “Global Burden of Cardiovascular Diseases: Projections From 2025 to 2050,” Europe PMC, europepmc.org} The ticagrelor market, therefore, depends on both initial hospital treatment and continuing care after an event. This pattern makes demand less dependent on a single acute dispensing episode.

Guideline-Led Preference Embeds Ticagrelor in Standard ACS Protocols

The 2025 ACC, AHA, ACEP, NAEMSP, and SCAI guideline recommends ticagrelor or prasugrel over clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. That recommendation supports ticagrelor use in hospital pathways where treatment choices are often set through clinical protocols. The same guideline supports a switch to ticagrelor monotherapy 1 month or later after percutaneous coronary intervention in suitable patients to lower bleeding risk while preserving ischemic protection. This approach can extend treatment beyond the earliest stage of dual antiplatelet therapy. European clinical guidance also discusses personalized antithrombotic treatment and ticagrelor-based de-escalation for selected patients. The shared direction of North American and European guidance helps maintain a clinical role for ticagrelor even when lower-priced products enter formularies.

Generic Access and Hospital Procurement Modernization Broaden Availability

Generic availability has changed the ticagrelor market from one centered on an originator brand to one with stronger price competition. Lower prices can make ticagrelor more accessible in hospital formularies and outpatient settings where treatment cost previously favored clopidogrel. This effect is important in procurement systems that select products through tenders and emphasize unit cost. The shift does not remove the need for clinical review because patients still require assessment of bleeding risk, dyspnea, and potential drug interactions. The ticagrelor market can benefit when hospital purchasing systems make potent antiplatelet therapy more affordable and available.

Stroke, TIA, and Extended Post-MI Protocols Expand Treatment Pathways

Ticagrelor plus aspirin reduced the combined risk of stroke or death within 30 days by 17% compared with aspirin alone in patients with acute ischemic stroke or high-risk transient ischemic attack in the THALES evidence base. The evidence gives the ticagrelor market a pathway into stroke care that is separate from its established cardiology use. New Zealand proposed public funding for ticagrelor for minor stroke and high-risk transient ischemic attack from November 2025, providing an early reimbursement example for this use. Extended therapy after myocardial infarction is another source of demand, particularly for the 60 mg dose. A 2024 study of a virtual ticagrelor service described a structured method for identifying eligible patients after myocardial infarction. These protocols require clinicians to identify suitable patients and manage continuation carefully, which links growth to clinical workflow as well as prescribing volume.

Bleeding, Dyspnea, and Treatment Complexity Limit Persistence

Bleeding and dyspnea can limit patient selection and continuation in the ticagrelor market. A 2024 study found dyspnea during the first month of ticagrelor-based dual antiplatelet therapy in 20.6% of patients.^{[3]Thrombosis and Haemostasis, “Clinical Impact of Dyspnea After Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients With Myocardial Infarction,” Thrombosis and Haemostasis, thieme-connect.com} Adherence was lower among patients who continued ticagrelor than among those de-escalated to clopidogrel, especially for patients with dyspnea, at 81.1% and 91.5%, respectively. A 2024 network meta-analysis also reported the highest risk of premature discontinuation for ticagrelor among the major P2Y12 inhibitors. These issues narrow the eligible patient group and make counseling, follow-up, and individualized risk assessment necessary. Aspirin dose considerations and drug interactions add further complexity when clinicians choose and monitor therapy.

Generic Price Erosion and Uneven Follow-Up Capacity Constrain Value

Generic competition can increase use while reducing the value captured in the ticagrelor market. AstraZeneca reported Brilinta revenue of USD 823 million in fiscal year 2025, down 38% from the prior year, as generic competition affected the franchise. The price effect is strongest where hospital and payer formularies switch quickly among therapeutically equivalent alternatives. It can reduce branded revenue without signaling a comparable decline in the number of treated patients. Uneven access to diagnosis, specialist follow-up, and medication review can also interrupt continuation of treatment in rural areas and in developing health systems. The ticagrelor market is consequently shaped by the ability of providers to sustain therapy after discharge, not only by their ability to start it during an acute event.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Dosage Strength: 90 mg Retains Scale While 60 mg Expands in Extended Care

The 90 mg formulation accounted for 63.18% of the segment value in 2025. Its position reflects its central use in acute and post-acute coronary syndrome treatment and in the stroke and transient ischemic attack setting. A loading dose followed by 90 mg twice daily during the first year after an acute coronary syndrome event supports regular hospital and outpatient replenishment. The formulation remains relevant where clinicians use guideline-based acute coronary care pathways. Price pressure is therefore more likely to change supplier choice than the clinical need for treatment.

The 60 mg formulation is forecast to grow at an 8.5% CAGR from 2026 to 2031, the highest rate within dosage strength. Extended dual antiplatelet therapy with ticagrelor 60 mg twice daily reduced cardiovascular death, myocardial infarction, or stroke in eligible patients with prior myocardial infarction in the PEGASUS evidence base.^{[4]Frontiers in Cardiovascular Medicine, “Supporting Appropriate Use of Extended Dual Antiplatelet Therapy Post-Myocardial Infarction Based on an Innovative 12-Month Ticagrelor Virtual Service,” Frontiers in Cardiovascular Medicine, frontiersin.org} European guidance favors the 60 mg dose for extended therapy after 12 months in suitable patients with prior myocardial infarction, while real-world persistence can still be affected by adverse effects and patient-led discontinuation. Electronic health record screening and pharmacist reviews can help identify patients who meet treatment criteria. Demand for 60 mg tablets, therefore, depends on consistent patient identification and support after the initial acute treatment period.

By Indication: ACS Remains the Largest Use While Ischemic Stroke Advances

Acute coronary syndrome represented 59.31% of the ticagrelor market size in 2025. It remains the largest indication because ticagrelor was established in coronary care and is supported by treatment guidance for patients undergoing percutaneous coronary intervention. The 2025 ACC, AHA, ACEP, NAEMSP, and SCAI guideline gives a Class I recommendation for ticagrelor or prasugrel over clopidogrel in this setting. It also supports ticagrelor monotherapy for selected patients after an initial period of dual therapy. Coronary artery disease prevention and extended treatment after myocardial infarction provide further use beyond the first acute episode.

Ischemic stroke is forecast to grow at an 8.6% CAGR from 2026 to 2031, making it the fastest-growing indication. The THALES evidence supports ticagrelor plus aspirin when treatment is initiated promptly after minor-to-moderate ischemic stroke or high-risk transient ischemic attack. A 2025 CHANCE-2 post hoc analysis assessed the groups that may benefit from aspirin and ticagrelor treatment, including patients without symptomatic carotid artery stenosis. The shorter 30-day treatment period differs from longer acute coronary syndrome maintenance courses and may reduce the discontinuation challenge. The ticagrelor market can serve neurologists and stroke services as reimbursement and clinical pathways develop.

By Distribution Channel: Hospital Pharmacies Lead While Online Pharmacies Grow

Hospital pharmacies held 46.18% of distribution value in 2025. This channel leads because ticagrelor is often initiated in emergency departments, catheterization laboratories, and coronary care units. Hospital pharmacists and clinical teams can provide counseling and assess bleeding, dyspnea, and concomitant medicines when treatment begins. The channel supports timely access to loading doses and initial dual antiplatelet therapy packs. Retail pharmacies, institutional supply, and tenders then support ongoing treatment after discharge.

Online pharmacies are forecast to grow at an 8.5% CAGR from 2026 to 2031. Digital refill platforms and electronic prescribing can support continuity for patients receiving longer-term 60 mg maintenance treatment. The channel gives patients clearer visibility of generic availability and price, but it remains focused on refills rather than acute treatment initiation. Online growth does not replace hospital oversight when a patient first receives ticagrelor. The ticagrelor market can grow through both channels because they support different points in the treatment journey.

Geography Analysis

North America accounted for 43.18% of the ticagrelor market share in 2025. High percutaneous coronary intervention volumes, clinical guideline use, and historically higher branded prices supported its leading position. Generic competition has lowered the price per unit while preserving access to treatment, and the 2025 acute coronary syndrome guideline continues to support ticagrelor use in appropriate patients undergoing percutaneous coronary intervention.^{[5]Sunil V. Rao et al., “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: Guideline-at-a-Glance,” Journal of the American College of Cardiology, jacc.org} Canada has entered a more active generic substitution phase following patent expiry. Mexico adds demand through expanded healthcare infrastructure and treatment of acute coronary syndrome in urban hospitals.

Europe is the second-largest contributor to ticagrelor revenues, and generic competition emerged in several countries before the U.S. shift. AstraZeneca reported that generic erosion in Europe contributed to the Brilinta decline reported for fiscal year 2024. Germany, the United Kingdom, and France remain major markets by volume, while Spain and Italy retain meaningful hospital use. European treatment guidance supports personalized antithrombotic approaches, including ticagrelor-based strategies for selected patients. South America grows through private hospital networks and public procurement, with Brazil and Argentina leading the region.

Asia-Pacific is forecast to grow at an 8.8% CAGR from 2026 to 2031, the fastest rate among regions. Rising cardiovascular incidence, hospital procurement modernization, and generic affordability support the ticagrelor market in this region. India recorded a 50% increase in cardiac drug sales between June 2021 and June 2025, indicating stronger institutional demand for cardiovascular medicines. China uses centralized procurement that can lower branded prices and favor suppliers that can fulfill large hospital tenders.